{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:16:18Z","timestamp":1769084178252,"version":"3.49.0"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background &amp; Aims<\/jats:title><jats:p>Adequate adherence to hepatitis C virus (HCV) treatment is believed to be a key component of treatment success because non\u2010adherence can potentially result in treatment failure and the emergence of resistant viral variants. This analysis assessed factors associated with non\u2010adherence to glecaprevir\/pibrentasvir (G\/P) therapy and the impact of non\u2010adherence on sustained virological response at post\u2010treatment week 12 (SVR12) rates in HCV genotype (GT) 1\u20106\u2010infected patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adherence was calculated by pill counts at study visits during treatment, and defined as having a lowest treatment adherence of \u226580% and \u2264120% at each study visit. Exploratory logistic regression modelling assessed predictors of non\u2010adherence to G\/P therapy. SVR12 rates by treatment adherence were assessed in the intent\u2010to\u2010treat (ITT) population and modified ITT (mITT) population, which excludes non\u2010virological failures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 97% (2024\/2091) of patients were adherent to G\/P therapy at all consecutive study visits. Alcohol use was the only baseline characteristic independently associated with non\u2010adherence to G\/P therapy (OR: 2.38; 95% CI: 1.13\u20105.01; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.022). In the mITT population, overall SVR12 rates were high both in patients who were adherent to G\/P therapy and those who were not (99% [1983\/2008] and 95% [58\/61] respectively; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.047). Corresponding SVR12 rates in the ITT population were 98% (1983\/2024) and 87% (58\/67) respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Most patients adhered to G\/P therapy. SVR12 rates were high both in patients who were adherent to G\/P treatment and those who were not. Patient education on treatment adherence should remain an important part of HCV treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trials registration<\/jats:title><jats:p>NCT02604017, NCT02640482, NCT02640157, NCT02636595, NCT02642432, NCT02651194, NCT02243293, NCT02446717.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.14266","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T05:38:22Z","timestamp":1569908302000},"page":"778-786","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Adherence to pan\u2010genotypic glecaprevir\/pibrentasvir and efficacy in HCV\u2010infected patients: A pooled analysis of clinical trials"],"prefix":"10.1111","volume":"40","author":[{"given":"Ashley","family":"Brown","sequence":"first","affiliation":[{"name":"Imperial College Healthcare NHS Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania M.","family":"Welzel","sequence":"additional","affiliation":[{"name":"Department of Medicine 1 J. W. Goethe University Hospital Frankfurt am Main Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Conway","sequence":"additional","affiliation":[{"name":"Vancouver Infectious Diseases Center Vancouver BC Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4046-4806","authenticated-orcid":false,"given":"Francesco","family":"Negro","sequence":"additional","affiliation":[{"name":"Divisions of Gastroenterology and Hepatology and Clinical Pathology Geneva University Hospital Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Br\u00e4u","sequence":"additional","affiliation":[{"name":"James J. Peters VA Medical Center Icahn School of Medicine at Mount Sinai New York City NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[{"name":"The Kirby Institute UNSW Sydney Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Puoti","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases AO Ospedale Niguarda Ca' Granda Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[{"name":"Humanitas University and Clinical and Research Hospital Rozzano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Kleine","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH &amp; Co KG Wiesbaden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pugatch","sequence":"additional","affiliation":[{"name":"AbbVie North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico J.","family":"Mensa","sequence":"additional","affiliation":[{"name":"AbbVie North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaozhu J.","family":"Chen","sequence":"additional","affiliation":[{"name":"AbbVie North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Lei","sequence":"additional","affiliation":[{"name":"AbbVie North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[{"name":"Texas Liver Institute University of Texas Health San Antonio San Antonio TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-0595","authenticated-orcid":false,"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[{"name":"Department of Hepatology Centre de Recherche sur l'Inflammation (CRI) INSERM UMR 1149 University of Paris Diderot AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,10,18]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"World Health Organization.Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis.http:\/\/apps.who.int\/iris\/bitstream\/10665\/246177\/1\/WHO-HIV-2016.06-eng.pdf?ua=1. Accessed April 12 2018."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ197"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.08.043"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13673"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S1458"},{"key":"e_1_2_9_7_1","unstructured":"BernsteinD MarinhoRT CohenDE et al.Adherence to prescribed doses of ABT\u2010450\/r\/ombitasvir dasabuvir and ribavirin in the phase 3 PEARL\u2010II PEARL\u2010III and PEARL\u2010IV trials. The Liver Meeting 2014. 7\u201311 November 2014 Boston MA USA. Abstract 1953."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9680-7"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004151"},{"key":"e_1_2_9_10_1","unstructured":"FosterGR GrebelyJ ShermanKE et al.Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis C genotypes 1\u20136 and recent drug use. The Liver Meeting 2017. 20\u201324 October 2017 Washington DC USA. Abstract 1182."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw580"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw579"},{"key":"e_1_2_9_13_1","unstructured":"GrebelyJ DoreGJ AlamiNN et al.Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic HCV genotypes 1\u20136 receiving opioid substitution therapy. 6th International Symposium on Hepatitis Care in Substance Users. 6\u20138 September 2017 New York NY USA."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0816"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30404-1"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000903"},{"key":"e_1_2_9_17_1","unstructured":"LitwinAH AgyemangL AkiyamaMJ et al.The PREVAIL study: intensive models of HCV care for people who inject drugs. The International Liver Congess 2017. 19\u201323 April 2017 Amsterdam The Netherlands. Abstract PS\u2010130."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.05.021"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.07.039"},{"key":"e_1_2_9_20_1","volume-title":"Maviret (glecaprevir and pibrentasvir)"},{"key":"e_1_2_9_21_1","volume-title":"Mavyret (glecaprevir and pibrentasvir)"},{"key":"e_1_2_9_22_1","volume-title":"Maviret (glecaprevir and pibrentasvir)"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.007"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","unstructured":"GaneE PoordadF ZadeikisN et al. Efficacy safety and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1\u20136 hepatitis C virus infection and compensated cirrhosis: an integrated analysis. The Liver Meeting 2017. 20\u201324 October 2017 Washington DC USA. Abstract 74.","DOI":"10.1016\/S0016-5085(17)33669-7"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702417"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.09.027"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29671"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_9_31_1","unstructured":"D'AmbrosioR PasuloL PuotiM et al.Real\u2010life effectiveness and safety of glecaprevir\/pibrentasvir among 723 Italian patients with chronic hepatitis C: the navigator\u2010II study. The International Liver Congess 2018. 11\u201315 April 2018 Paris France. Abstract GS\u2010013."},{"key":"e_1_2_9_32_1","unstructured":"CornbergM NaumannU StoehrA et al.Real\u2010world data on safety and effectiveness of glecaprevir\/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: latest results from the German hepatitis C\u2010registry. 16th Annual International Symposium on Viral Hepatitis and Liver Disease's GLOBAL HEPATITIS SUMMIT 2018. 14\u201317 June 2018; Toronto Ontario Canada. Abstract LBP\u2010007."}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.14266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.14266","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T01:24:16Z","timestamp":1694049856000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.14266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,18]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1111\/liv.14266"],"URL":"https:\/\/doi.org\/10.1111\/liv.14266","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,18]]},"assertion":[{"value":"2019-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}